Cycloastragenol Attenuates Osteoclastogenesis and Bone Loss by Targeting RANKL-Induced Nrf2/Keap1/ARE, NF-κB, Calcium, and NFATc1 Pathways

Overview of attention for article published in Frontiers in Pharmacology, January 2022

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 22 Dimensions

Readers on

mendeley: 4 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 22 publications that cite this research output.

22

The most recent citing publications are shown below. View all 22 publications that cite this research output on Dimensions.

Cycloastragenol prevents bone loss via inhibiting osteoclast activity in glucocorticoid-induced osteonecrosis of the femoral head: An in vivo study

Article in Journal of Orthopaedic Translation (March 2024)

Anti-osteoporosis activity of casticin in ovariectomized rats

Article in Toxicology Research (March 2024)

Involvement of the Keap1-Nrf2-ARE pathway in the antioxidant activity of sinomenine

Article in Archives of Biochemistry and Biophysics (February 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.